- POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors
- Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems
- Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix Venture Partners, Board Observer for Madorra Inc., board advisory roles at multiple value-generating healthcare companies
- Past experience includes role as founding CEO of OneCity Health Services, subsidiary of NYC Health + Hospitals
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently appointed strategic advisor and venture investor Dr. Christina Jenkins to its board of directors.
Dr. Jenkins synergizes capital markets expertise with healthcare industry experience through roles that span clinical medicine, venture capital, healthcare systems and health plans. Her unique set of skills, bolstered by her multivariate perspective and extensive experience, have enabled her to create growth-optimizing strategies for healthcare providers while improving health outcomes for patients.
“We are very fortunate to have Dr. Jenkins join our Board of Directors,” said POAI Chief Executive Officer J. Melville Engle. “As a medical doctor she brings additional insight and perspectives to our team. She has participated and led companies to success in health services and will have an immediate impact at Predictive Oncology and will strengthen our strategic positioning in the market.”
Dr. Jenkins brings extensive experience to POAI through multiple leadership roles across the healthcare space. She is a Board Director for Independence Health Group—the parent organization of Independence Blue Cross and AmeriHealth Caritas—in addition to being a Board Observer for Madorra Inc., a wellness company focused on women’s gynecological health. As a Venture Partner at Phoenix Venture Partners, Dr. Jenkins co-leads the firm’s seed-stage investment strategy in the healthcare/life sciences vertical with a focus on hardware-enabled platform companies that provide innovative ways to diagnose, monitor, and treat health conditions.
Dr. Jenkins’ prior experience includes work as the founding CEO of OneCity Health Services, a subsidiary of NYC Health + Hospitals, where she led a team of 130 people in a successful $1.2B effort to design and implement technology-enabled care models and accelerate value-based payment readiness that reduced financial risk for over one million people. In addition to being an advisory board member of multiple value-generating healthcare companies, Dr. Jenkins also leads investment strategies for Portfolia’s FemTech and Active Aging and Longevity funds.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
